Form 4: Rhythm Pharmaceuticals Director Jean Acquires RYTM Stock
Statement of Changes in Beneficial Ownership
Jean Christophe, a Director at Rhythm Pharmaceuticals, Inc., has acquired 4,712 shares of common stock and been granted stock options.
Summary
- Director Jean Christophe acquired 4,712 shares of Rhythm Pharmaceuticals, Inc. common stock on June 23, 2026.
- Additionally, Christophe was granted stock options to acquire 3,691 shares of common stock, exercisable on June 24, 2026, with an expiration date of June 23, 2036.
- Further, 2,324 restricted stock units were granted to Christophe on June 24, 2026, which vest on June 24, 2027, or the day before the next annual meeting in 2027, subject to continued service.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects standard insider transactions that can signal confidence but do not represent new company performance data.
Positives
- Director Jean Christophe's acquisition of common stock and grant of stock options indicates continued confidence and investment in the company.
- The acquisition of 4,712 shares of common stock directly increases beneficial ownership.
- The grant of 3,691 stock options provides potential future upside for the reporting person.
- The grant of 2,324 restricted stock units aligns management incentives with long-term company performance.
Future Outlook
The filing details grants of stock options and restricted stock units with vesting schedules tied to future dates, indicating management's long-term incentive structure.
Industry Context
StockSavvy.ai notes that insider transactions, such as stock acquisitions and option grants, are common for directors and executives in the biotechnology and pharmaceutical sectors as a means of aligning their interests with shareholders and incentivizing performance.
Stakeholder Impact
- Shareholders: The acquisition of stock by a director can be viewed positively, suggesting alignment of interests. The granting of options and RSUs is a standard compensation practice.
Next Steps
- Vesting of stock options on June 24, 2027, or prior to the 2027 annual meeting.
- Vesting of restricted stock units on June 24, 2027, or prior to the 2027 annual meeting.
Key Dates
| Date | Description |
|---|---|
| 06/23/2026 | Earliest transaction date and date of common stock acquisition. |
| 06/24/2026 | Date of stock option grant and restricted stock unit grant. |
| 06/23/2036 | Expiration date for stock options. |
| 06/24/2027 | Vesting date for restricted stock units (earlier of this date or day before next annual meeting in 2027). |
Keywords
Form 4, SEC Filing, Rhythm Pharmaceuticals, RYTM, Stock Acquisition, Stock Options, Restricted Stock Units, Director, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.